These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36693416)

  • 41. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Zafar Y; Rashid AM; Siddiqi AK; Ellahi A; Ahmed A; Hussain HU; Ahmed F; Menezes RG; Siddiqi TJ; Maniya MT
    Clin Res Hepatol Gastroenterol; 2022; 46(7):101970. PubMed ID: 35659603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
    Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
    Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.
    Katsiki N; Kazakos K; Triposkiadis F
    Expert Opin Pharmacother; 2022 Dec; 23(17):1957-1974. PubMed ID: 36322877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
    Giugliano D; Longo M; Signoriello S; Maiorino MI; Solerte B; Chiodini P; Esposito K
    Cardiovasc Diabetol; 2022 Mar; 21(1):42. PubMed ID: 35296336
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes.
    Cha AS; Chen Y; Fazioli K; Rivara MB; Devine EB
    J Clin Endocrinol Metab; 2021 Mar; 106(4):1225-1234. PubMed ID: 33248440
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [New oral hypoglycemic drugs in diabetic kidney disease].
    Dylewska M; Graczyk M
    Wiad Lek; 2017; 70(6 pt 2):1193-1196. PubMed ID: 29533912
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiometabolic Effects of a New Class of Antidiabetic Agents.
    Desouza CV; Gupta N; Patel A
    Clin Ther; 2015 Jun; 37(6):1178-94. PubMed ID: 25754876
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes.
    Siasos G; Bletsa E; Stampouloglou PK; Paschou SA; Oikonomou E; Tsigkou V; Antonopoulos AS; Vavuranakis M; Tousoulis D
    Curr Pharm Des; 2020; 26(46):5911-5932. PubMed ID: 33167826
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).
    Liakos CI; Papadopoulos DP; Sanidas EA; Markou MI; Hatziagelaki EE; Grassos CA; Velliou ML; Barbetseas JD
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):123-137. PubMed ID: 32780214
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Features of the course of COVID-19 in patients with type 2 diabetes mellitus].
    Karaseva EA; Martynov VA; Filatova TE; Maleev VV; Grishin VY; Pronin NS; Verbitskaya EI; Popova VI
    Ter Arkh; 2023 Dec; 95(11):913-918. PubMed ID: 38158945
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists.
    Eckerle Mize DL; Salehi M
    Curr Diab Rep; 2013 Jun; 13(3):307-18. PubMed ID: 23479200
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.
    Hong D; Si L; Jiang M; Shao H; Ming WK; Zhao Y; Li Y; Shi L
    Pharmacoeconomics; 2019 Jun; 37(6):777-818. PubMed ID: 30854589
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis.
    Jin Y; Zhao H; Hou Y; Song G
    Acta Diabetol; 2020 Oct; 57(10):1129-1144. PubMed ID: 32300876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany.
    Jacob L; Rickwood S; Rathmann W; Kostev K
    Diabetes Obes Metab; 2021 Apr; 23(4):910-915. PubMed ID: 33319440
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors.
    Ohki T; Isogawa A; Toda N; Tagawa K
    Clin Drug Investig; 2016 Apr; 36(4):313-9. PubMed ID: 26914659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.